Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CELZ 
Creative Medical Technology Holdings Inc (CELZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: CELZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.28% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.80M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 5.22 | 52 Weeks Range 1.69 - 6.90 | Updated Date 10/14/2025 |
52 Weeks Range 1.69 - 6.90 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -98656.76% |
Management Effectiveness
Return on Assets (TTM) -49.02% | Return on Equity (TTM) -79.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1713582 | Price to Sales(TTM) 1466.6 |
Enterprise Value 1713582 | Price to Sales(TTM) 1466.6 | ||
Enterprise Value to Revenue 285.6 | Enterprise Value to EBITDA -1.45 | Shares Outstanding 2580532 | Shares Floating 2179724 |
Shares Outstanding 2580532 | Shares Floating 2179724 | ||
Percent Insiders 1.37 | Percent Institutions 8.03 |
Upturn AI SWOT
Creative Medical Technology Holdings Inc
Company Overview
History and Background
Creative Medical Technology Holdings, Inc. was founded to pursue regenerative medicine and immunotherapy solutions. While the founding year and specific milestones are less publicly documented compared to larger companies, its focus is on developing novel therapies.
Core Business Areas
- Stem Cell Therapeutics: Develops stem cell-based therapies targeting various diseases, including cardiovascular and autoimmune conditions.
- Immunotherapy: Focuses on innovative immunotherapy approaches to combat cancers and other immune-related disorders.
- AmnioVerseu2122 Technology Platform: Develops and commercializes products derived from amniotic fluid and tissues, expanding into regenerative and aesthetic medicine.
Leadership and Structure
Details about the leadership team and organizational structure are available on their corporate website, typically outlining the CEO, CFO, and key scientific personnel. The structure likely reflects a research-driven organization.
Top Products and Market Share
Key Offerings
- StemSpineu00ae: A stem cell therapy for chronic lower back pain. Market share data is difficult to ascertain precisely, as the regenerative medicine market is highly fragmented and evolving. Competitors include companies developing similar stem cell-based therapies and traditional pain management solutions. It is difficult to provide market share data because clinical trials are ongoing.
- FemCelzu00ae: A cell therapy for female sexual dysfunction. Market share data is not publicly available. Competitors include pharmaceutical companies and those offering alternative therapies. It is difficult to provide market share data because clinical trials are ongoing.
- AmnioVerseu2122: A platform to create products using amniotic fluid for regenerative and aesthetic applications. Market share data is still evolving due to product development and potential new entrants. Competitors include similar products from other companies in aesthetic medicine.
Market Dynamics
Industry Overview
The regenerative medicine and immunotherapy industries are experiencing substantial growth, driven by increasing demand for advanced therapies and breakthroughs in biotechnology.
Positioning
Creative Medical Technology Holdings is positioned as an innovator within these sectors, focusing on proprietary stem cell and immunotherapy technologies. Its competitive advantage hinges on the efficacy and safety of its therapies.
Total Addressable Market (TAM)
The global regenerative medicine market is projected to reach hundreds of billions of dollars. The company is strategically positioned to capture a share of this market through its pipeline of products and ongoing clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- Innovative therapeutic approaches
- Strong focus on research and development
- Intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on successful clinical trial outcomes
- Commercialization risks
- Regulatory hurdles
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Increasing market acceptance of regenerative medicine
- Potential for breakthrough therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- Mesoblast Limited (MESO)
- Vertex Pharmaceuticals (VRTX)
- BioTime, Inc. (BTX)
Competitive Landscape
Creative Medical Technology Holdings faces significant competition from larger, well-established companies with greater financial resources. Its competitive advantage lies in its novel technologies and targeted therapeutic approaches, but it must overcome regulatory hurdles and commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and strategic partnerships.
Future Projections: Future growth projections are highly dependent on the success of its clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for StemSpineu00ae and FemCelzu00ae, and expanding its AmnioVerseu2122 platform.
Summary
Creative Medical Technology Holdings is a high-risk, high-reward company focused on regenerative medicine and immunotherapy. Its proprietary technology and innovative therapies offer significant potential, but it faces challenges related to funding, regulatory approval, and competition. Successful clinical trial outcomes are crucial for future success. The company's AmnioVerse platform provides additional revenue streams and diversification.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Creative Medical Technology Holdings Inc
Exchange NASDAQ | Headquaters Phoenix, AZ, United States | ||
IPO Launch date 2015-11-06 | Co-Founder, Chairman, President & CEO Mr. Timothy Warbington | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.